Shots:

• The abstract title was, ‘PD-L1 photoimmunotherapy kills immunosuppressive myeloid cells to activate local and systemic antitumor immunity’
• The in vitro study depicted its dual MOA of reducing PD-L1 expressing tumor cells & immunosuppressive cells like TAMs & MDSCs plus systemic immune checkpoint inhibition; in vivo study showed effective tumor growth suppression than anti-PD-L1 Ab alone & saline control in anti-PD-L1 sensitive & resistant mouse tumor models, respectively
• In vivo studies also showed decreased immunosuppressive tumor microenvironment cells & enhanced CD8+ T cell activation to maintain checkpoint inhibition. RM-0256 was well-tolerated when given repeatedly to cynomolgus monkeys in a GLP toxicity study

Ref: Rakuten | Image: Rakuten

Related News: Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com